Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

J. Lewerich; S. C. Schmid; J. E. Gschwend; M. Retz

doi:10.1007/s00120-022-01983-5

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

Translated title of the contribution: Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer

J. Lewerich
, S. C. Schmid
, J. E. Gschwend
, M. Retz

Technical University of Munich
Interdisziplinare Arbeitsgruppe BlasenCarcinom (IABC) der DKG e. V.

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Immune checkpoint inhibitors are standard of care in the treatment of metastatic and locally advanced urothelial cancer. Their use in perioperative treatment is currently under investigation as monotherapy as well as in combination with chemotherapy or radiation regimens. This article provides an overview of recent trials, current data as well as an outlook on future developments in the perioperative management of urothelial cancer.

Translated title of the contribution	Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer
Original language	German
Pages (from-to)	279-287
Number of pages	9
Journal	Urologie
Volume	62
Issue number	3
DOIs	https://doi.org/10.1007/s00120-022-01983-5
State	Published - Mar 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-022-01983-5

Cite this

@article{0190a30f51d4455ca31d2daae7e738c9,

title = "Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms",

abstract = "Immune checkpoint inhibitors are standard of care in the treatment of metastatic and locally advanced urothelial cancer. Their use in perioperative treatment is currently under investigation as monotherapy as well as in combination with chemotherapy or radiation regimens. This article provides an overview of recent trials, current data as well as an outlook on future developments in the perioperative management of urothelial cancer.",

keywords = "Bladder cancer, Chemotherapy, Immune checkpoint inhibitors, Perioperative therapy, Radical cystectomy",

author = "J. Lewerich and Schmid, \{S. C.\} and Gschwend, \{J. E.\} and M. Retz",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2023",

month = mar,

doi = "10.1007/s00120-022-01983-5",

language = "Deutsch",

volume = "62",

pages = "279--287",

journal = "Urologie",

issn = "2731-7064",

publisher = "Springer Medizin",

number = "3",

}

TY - JOUR

T1 - Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

AU - Lewerich, J.

AU - Schmid, S. C.

AU - Gschwend, J. E.

AU - Retz, M.

PY - 2023/3

Y1 - 2023/3

N2 - Immune checkpoint inhibitors are standard of care in the treatment of metastatic and locally advanced urothelial cancer. Their use in perioperative treatment is currently under investigation as monotherapy as well as in combination with chemotherapy or radiation regimens. This article provides an overview of recent trials, current data as well as an outlook on future developments in the perioperative management of urothelial cancer.

AB - Immune checkpoint inhibitors are standard of care in the treatment of metastatic and locally advanced urothelial cancer. Their use in perioperative treatment is currently under investigation as monotherapy as well as in combination with chemotherapy or radiation regimens. This article provides an overview of recent trials, current data as well as an outlook on future developments in the perioperative management of urothelial cancer.

KW - Bladder cancer

KW - Chemotherapy

KW - Immune checkpoint inhibitors

KW - Perioperative therapy

KW - Radical cystectomy

UR - https://www.scopus.com/pages/publications/85143124295

U2 - 10.1007/s00120-022-01983-5

DO - 10.1007/s00120-022-01983-5

M3 - Artikel

AN - SCOPUS:85143124295

SN - 2731-7064

VL - 62

SP - 279

EP - 287

JO - Urologie

JF - Urologie

IS - 3

ER -

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this